Objects
Abouyannis, Michael, Esmail, Hanif, Alcoba, Gabriel, Cammack, Nick, Chippaux, Jean-Philippe, Coldiron, Matthew E., Gutiérrez, José M., Habib, Abdulrazaq G., Harrison, Robert A., Isbister, Geoffrey K., Lavonas, Eric J., Martins, Diogo, Hamaluba, Mainga, Ribeiro, Isabela, Watson, JA, Williams, DJ, Casewell, NR, Walker, SA, Lalloo, DG, Snakebite Global Core Outcome Set Study Group,, Ngama, Mwanajuma, Mwangudzah, Hope, Mumba, Noni, Yeri, Betty K., Mwalukore, Salim, Alphan, Hassan J., Aggarwal, Dinesh. Lancet Publishing Group; 2023. A Global Core Outcome Measurement Set for Snakebite Clinical Trials.
Coutts, Shelagh B., Ankolekar, Sandeep, Camden, Marie-Christine, Campbell, Bruce C. V., Casaubon, Leanne K., Catanese, Luciana, Chatterjee, Kausik, Choi, Philip M. C., Clarke, Brian, Dowlatshahi, Dar, Ferrari, Julia, Field, Thalia S., Appireddy, Ramana, Ganesh, Aravind, Ghia, D, Goyal, M, Greisenegger, S, Halse, O, Horn, M, Hunter, G, Imoukhuede, O, Kelly, PJ, Kennedy, J, Arenillas, Juan F., Kenney, C, Kleinig, TJ, Krishnan, K, Lima, F, Mandzia, JL, Marko, M, Martins, SO, Medvedev, G, Menon, BK, Mishra, SM, Assis, Zarina, Molina, C, Moussaddy, A, Muir, KW, Parsons, MW, Penn, AMW, Pille, A, Pontes-Neto, OM, Roffe, C, Serena, J, Simister, R, Bailey, Peter, Singh, N, Spratt, Neil, Strbian, D, Tham, CH, Wiggam, MI, Williams, DJ, Willmot, MR, Wu, T, Yu, AYX, Zachariah, G, Barber, Philip A., Zafar, A, Zerna, C, Hill, MD, Salluzzi, M, Blenkin, N, Dueck, A, Doram, C, Zhang, Q, Ryckborst, K, Bohn, S, Bazan, Rodrigo, Collier, Q, Taylor, F, Lethebe, BC, Jambula, A, Sage, K, Toussaint, L, Save, S, Lee, J, Laham, N, Sultan, AA, Buck, Brian H., Deepak, A, Sitaram, A, Demchuk, AM, Lockey, A, Micielli, A, Wadhwa, A, Arabambi, B, Graham, B, Bogiatzi, C, Doshi, D, Butcher, Ken S., Chakraborty, D, Kim, D, Vasquez, D, Singh, D, Tse, D, Harrison, E, Smith, EE, Teleg, E, Klourfeld, E, Klein, G. The Lancet Publishing Group; 2024. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.